AEHR vs. TXG, TRNS, EYPT, ALNT, LAB, CTKB, SENS, QSI, QTRX, and MASS
Should you be buying Aehr Test Systems stock or one of its competitors? The main competitors of Aehr Test Systems include 10x Genomics (TXG), Transcat (TRNS), Eyepoint Pharmaceuticals (EYPT), Allient (ALNT), Standard BioTools (LAB), Cytek Biosciences (CTKB), Senseonics (SENS), Quantum-Si (QSI), Quanterix (QTRX), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.
Aehr Test Systems vs. Its Competitors
10x Genomics (NASDAQ:TXG) and Aehr Test Systems (NASDAQ:AEHR) are both small-cap measuring and control equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.
Aehr Test Systems has a net margin of -6.63% compared to 10x Genomics' net margin of -25.14%. Aehr Test Systems' return on equity of -0.15% beat 10x Genomics' return on equity.
10x Genomics currently has a consensus target price of $13.23, suggesting a potential downside of 6.26%. Given 10x Genomics' stronger consensus rating and higher probable upside, analysts plainly believe 10x Genomics is more favorable than Aehr Test Systems.
84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 69.7% of Aehr Test Systems shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by insiders. Comparatively, 6.2% of Aehr Test Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
10x Genomics has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Aehr Test Systems has a beta of 2.29, indicating that its stock price is 129% more volatile than the S&P 500.
Aehr Test Systems has lower revenue, but higher earnings than 10x Genomics. Aehr Test Systems is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aehr Test Systems had 7 more articles in the media than 10x Genomics. MarketBeat recorded 17 mentions for Aehr Test Systems and 10 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 1.04 beat Aehr Test Systems' score of 0.45 indicating that 10x Genomics is being referred to more favorably in the media.
Summary
10x Genomics and Aehr Test Systems tied by winning 8 of the 16 factors compared between the two stocks.
Get Aehr Test Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEHR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AEHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aehr Test Systems Competitors List
Related Companies and Tools
This page (NASDAQ:AEHR) was last updated on 7/25/2025 by MarketBeat.com Staff
